Is Supernus Pharmaceuticals Inc (SUPN) a Bargain After 3.3% Drop? GF Value Says UndervaluedGuruFocus · 23 hr ago
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to DeclineZacks Investment Research · 2 days ago
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)GlobeNewsWire · 2 days ago
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026GlobeNewsWire · 5 days ago
Supernus Pharmaceuticals: The Merger Is Priced Like A Retreat, But Reads Like A Reverse TakeoverSeeking Alpha · Oct 16, 2026
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Rated “Hold” by Sell-Side BrokeragesDefense World · Oct 13, 2026Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 3, 2026 | $0.42 | $0.54 | Beat |
| May 5, 2026 | $0.28 | $0.59 | Beat |
| Feb 24, 2026 | $0.28 | $0.92 | Beat |
| Nov 4, 2025 | $0.82 | $1.01 | Beat |
| Aug 5, 2025 | $0.47 | $0.91 | Beat |
| May 6, 2025 | $0.38 | $0.42 | Beat |